Access is not one rule. It is a set of conditions that vary
An oncology portfolio team needed a working view of market access in Brazil.
Reimbursement in oncology is not decided by a single criterion. It is decided by drivers that carry different weight in different parts of the landscape, and by evidence expectations that are not always written down.
Pricing and reimbursement therefore have to be read together. A price that works under one set of conditions may not survive another.
Payers and clinicians, asked about the same decisions
The work was primary market research with payers and clinicians across the oncology landscape.
Both groups matter and they answer different halves of the question. Payers set the conditions. Clinicians decide what actually gets used within them.
The output was built as a comparative benchmark rather than a description. Comparability is what makes it usable for a portfolio decision, where the question is always relative.
Three things were covered consistently: the reimbursement drivers, the evidence expectations behind them, and the pricing considerations that follow.
The conditions, side by side and what they mean for the portfolio
The research identified the reimbursement drivers operating across the landscape.
It set out the evidence expectations attached to them, which is the part that determines what a dossier has to carry.
And it covered the pricing considerations that sit alongside both.
Together those made a comparative access benchmark. The client used it to inform portfolio strategy and value strategy, which is a different use from informing a single submission.
